Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,248 across all filing types
Latest filing 2019-05-23 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Code of Conduct under SEBI(PIT) Reg., 2015
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, regarding the approval and adoption of an amended 'Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information' by the Board of Directors. It includes detailed policy information about insider trading regulations, fair disclosure principles, and legitimate purposes for sharing unpublished price sensitive information. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory compliance announcement related to insider trading policies and fair disclosure practices, not a financial report or earnings release. It is a formal regulatory filing informing the stock exchange and public about the adoption of a compliance code as required by SEBI regulations. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (12,280 characters) and content confirm it is not a brief announcement but a full regulatory compliance document, yet it does not fit into other specific categories like Annual Report, Earnings Release, or Management Reports.
2019-05-23 English
This is to inform you that pursuant to the SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018, the Board of Directors of the Company has approved and adopted amended 'Code ....
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, regarding the approval and adoption of an amended 'Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information' by the Board of Directors. It includes detailed policy information about insider trading regulations, fair disclosure principles, and legitimate purposes for sharing unpublished price sensitive information. The document is not a financial report, earnings release, or management discussion but rather a regulatory compliance disclosure related to insider trading and fair disclosure practices. It is a formal announcement of a regulatory compliance policy adopted by the Board, not a report or financial statement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-05-23 English
Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Registrar and Share Transfer ....
Regulatory Filings Classification · 95% confidence The document is an intimation regarding the loss of share certificates and the issuance of duplicate share certificates under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It involves a notification about share certificate transmission due to loss and legal heir requests. There is no financial data, no report attached or referenced, no management discussion, no earnings data, no voting results, no board changes, no capital changes, and no legal proceedings. This is a regulatory compliance announcement related to share certificate handling, which fits best under Regulatory Filings (RNS) as it does not fit any other specific category.
2019-05-21 English
Enclosed herewith investor presentation on Company's performance for the quarter and year ended March 31, 2019. Kindly take the same on record.
Investor Presentation Classification · 95% confidence The document is titled as an "Investor Presentation on Company's performance for the quarter and year ended March 31, 2019." It contains detailed financial data including quarterly and annual standalone and consolidated income statements, balance sheets, operational highlights, and performance metrics such as EBITDA, PAT, and EPS. The presence of detailed financial tables and operational commentary indicates this is a comprehensive presentation aimed at investors. The document length is substantial (15,000 characters), and it is not merely an announcement or a brief summary. The content matches the description of an Investor Presentation (IP) rather than an Earnings Release (ER), which typically contains only key highlights, or an Annual Report (10-K), which is more comprehensive and formal. Therefore, the document is best classified as an Investor Presentation (IP).
2019-05-21 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled as an "Investor Presentation on Company's performance for the quarter and year ended March 31, 2019." It contains detailed financial data including quarterly and annual standalone and consolidated income statements, balance sheets, operational highlights, and performance metrics. The presence of slides and summary style presentation with charts and bullet points further supports that this is a presentation document. The document length is substantial (15,000 characters), and it contains actual financial data and analysis rather than just an announcement or certification. Therefore, it fits the definition of an Investor Presentation (IP).
2019-05-21 English
Press Release
Earnings Release Classification · 95% confidence The document is a newspaper advertisement of audited financial results for the quarter and year ended March 31, 2019, published on May 21, 2019. It includes extracts of standalone and consolidated financial results, with detailed financial figures such as total income, PAT, EBITDA, EPS, and PBT for the quarter and year ended March 31, 2019. The document references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and mentions that the full detailed financial results are filed with stock exchanges and available on their websites. The document is not the full annual report but an extract of audited financial results published as a newspaper advertisement. This type of document is typically classified as an Earnings Release (ER) because it announces key financial results for a quarter and fiscal year, highlighting key financial metrics but not providing the full annual report or detailed management discussion. The document length (15,000 characters) and content support it being a financial results announcement rather than a full annual report or other filing type.
2019-05-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.